Trillium Therapeutics Inc (TRIL)

[NY1972]

Alexo Therapeutics is developing novel, high-affinity SIRPa variants to increase macrophage phagocytosis activity induced by tumor-specific antibodies. Soluble versions of SIRPa have been engineered to bind CD47 with significantly greater affinity than natural SIRPa.2 Our proprietary candidates include fusion proteins that work in combination with anticancer antibodies to increase targeted phagocytosis, without carrying a pro-phagocytic signal to a variety of non-cancerous cells. Our goal is to develop immunotherapeutic adjuvants for use with broad combinations of antibodies to improve their therapeutic effectiveness.

http://alexotherapeutics.com/science-main.html